Original Article | Published:

Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial

International Journal of Obesity volume 30, pages 15451556 (2006) | Download Citation

Subjects

Abstract

Objective:

To determine the safety and efficacy of a dietary supplement with a low dose of ephedra and caffeine in overweight/obese premenopausal female subjects.

Design:

A 9-month, double-blind, randomized control study compared the efficacy and safety of a dietary supplement with ephedra and caffeine to a control supplement.

Subjects:

Sixty-one healthy, premenopausal women with body mass index (BMI) from 27 to 39 kg/m2 were randomly assigned and received a dietary supplement (40 mg/day ephedra alkaloids, 100 mg/day caffeine, high potency mixture of vitamins, minerals, omega-3 fatty acids) or a control supplement for 9 months.

Measurements:

Efficacy: changes in body weight, body composition, lipids, insulin, leptin, adiponectin, ghrelin, and self-reports of physical activity, diet and quality of life indices. Safety: blood pressure, heart rate, electrocardiograms, urinalysis, blood histology, serum chemistry measures and self-reported symptoms.

Results:

Forty-one women completed the study. The treatment group lost significantly more body weight (−7.18 kg) and body fat (−5.33 kg) than the control group (−2.25 and −0.99 kg, respectively), and showed significant declines in heart rate, serum cholesterol, triglycerides, cholesterol to high-density lipoprotein ratio, glucose, fasting insulin, and leptin. Blood pressure, electrocardiograms, other clinical chemistry measures, blood histology, urinalysis, and self-reported physical activity were similar in the groups. Minor symptoms included dry mouth, insomnia, nervousness and palpitations. The treatment group reported more energy and decreased appetite compared to controls and scored higher on a quality of life domain assessing vitality.

Conclusion:

A dietary supplement containing a low potency ephedra/caffeine mixture appeared safe and effective in causing loss of weight and body fat, and improving several metabolic parameters, including insulin sensitivity and lipid profiles when tested under physician supervision. Such supplements could be a useful tool to assist with weight loss.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , . Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 1723–1727.

  2. 2.

    , , , . Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998; 22: 39–47.

  3. 3.

    , , . State-level estimates of annual medical expenditures attributable to obesity. Obes Res 2004; 12: 18–24.

  4. 4.

    , , , . National patterns of physician activities related to obesity management. Arch Fam Med 2000; 9: 631–638.

  5. 5.

    , , , , , . Obese women's perceptions of their physicians' weight management attitudes and practices. Arch Fam Med 2000; 9: 854–860.

  6. 6.

    , , , , . The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 1992; 16: 269–277.

  7. 7.

    , , , , , . An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord 2001; 25: 316–324.

  8. 8.

    , , , , , et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26: 593–604.

  9. 9.

    Department of Health and Human Services, Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Available at: . Accessed April 12, 2004.

  10. 10.

    . Randomization. [website]. July 27, 2003. Available at . Accessed November 18, 2002.

  11. 11.

    , , . Use of bio-impedance spectroscopy (BIS) to determine extracellular fluid (ECF), intracellular fluid (ICF), total body water (TBW), and fat free mass (FFM). In: Ellis KJ, Eastman JD (eds). Human Body Composition. Plenum Press: New York, 1993. pp 67–70.

  12. 12.

    , , , , , , . Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460–2470.

  13. 13.

    Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–2446.

  14. 14.

    , , . Tonic sympathetic nervous system inhibition of insulin secretion is diminished in obese Zucker rats. Obesity Res 1993; 1: 371–376.

  15. 15.

    , , , , , . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

  16. 16.

    United Stated Department of Health and Human Services. Coding Symbol and Thesaurus for Adverse Event Terminology (COSTART). US Department of Health and Human Services: Rockville, MD, 1990.

  17. 17.

    , , , . Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990; 43: 1327–1335.

  18. 18.

    , , , , , et al. Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments. Am J Epidemiol 1985; 122: 794–804.

  19. 19.

    , . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.

  20. 20.

    , , , . Applied Linear Statistical Models 4th edn. Chicago: Irwin, 1995.

  21. 21.

    , . Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 2001; 20: 3931–3946.

  22. 22.

    , , . Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 2003; 4: 175–184.

  23. 23.

    SAS Institute I. The SAS System for Windows, Version 9.1. SAS Institute: Cary, NC, 2003.

  24. 24.

    , . Transformations, means and confidence intervals. BMJ 1996; 312: 1079.

  25. 25.

    , . Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343: 1833–1838.

  26. 26.

    , , , , , et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537–1545.

  27. 27.

    , , , , , . Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA 2004; 291: 216–221.

  28. 28.

    , , . Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 2002; 71: 421–432.

  29. 29.

    , , , , . Effect of a dietary herbal supplement containing caffeine and ephedra on weight, metabolic rate, and body composition. Obes Res 2004; 12: 1152–1157.

  30. 30.

    , , , . A randomized double-blind placebo-controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. Int J Obes Relat Metab Disord 2004; 28: 1411–1419.

  31. 31.

    , . Vitamins for chronic disease prevention in adults: scientific review. JAMA 2002; 287: 3116–3126.

  32. 32.

    , , , , . Association of low plasma concentrations of antioxidant vitamins, magnesium and zinc with high body fat per cent measured by bioelectrical impedance analysis in Indian men. Magnesium Res 1998; 11: 3–10.

  33. 33.

    , , . Zinc may be a mediator of leptin production in humans. Life Sci. 2000; 66: 2143–2149.

  34. 34.

    , . The effect of (−)-hydroxycitrate on energy intake and satiety in overweight humans. Int J Obes Relat Metab Disord 2002; 26: 870–872.

  35. 35.

    , , , , , et al. Dose- and time-dependent effects of a novel (−)-hydroxycitric acid extract on body weight, hepatic and testicular lipid peroxidation, DNA fragmentation and histopathological data over a period of 90 days. Mol Cell Biochem 2003; 254: 339–346.

  36. 36.

    , , , . Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women. Metabolism 1998; 47: 429–434.

  37. 37.

    , , . Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women. Am J Clin Nutr 1998; 68: 794–801.

  38. 38.

    , , , , . Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002; 87: 2391–2394.

  39. 39.

    . Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004; 53: S143–S151.

  40. 40.

    , , , , , et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623–1630.

  41. 41.

    , , , , , . Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594–1602.

  42. 42.

    , , , , , et al. A prospective study of weight change and health-related quality of life in women. JAMA 1999; 282: 2136–2142.

  43. 43.

    , , , , . Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993; 17 (Suppl 1): S73–S78.

  44. 44.

    . Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord 1993; 17 (Suppl 1): S35–S40.

  45. 45.

    , , . Short-term metabolic and hemodynamic effects of ephedra and guarana combinations. Clin Pharmacol Ther 2005; 77: 560–571.

  46. 46.

    , , , , . Short-term and long-term in vivo exposure to an ephedra- and caffeine-containing metabolic nutrition system does not induce cardiotoxicity in B6C3F1 mice. Arch Toxicol 2005; 79: 330–340.

  47. 47.

    , . Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461–1468.

Download references

Acknowledgements

We thank Kimberley Hansen BS for her clinical skills and Kimber Stanhope and James Graham for their technical assistance with the endocrine assays. The study was supported in part by an unrestricted gift from AdvoCare International, LP, Carrollton, TX.

Author information

Affiliations

  1. Department of Nutrition, University of California, Davis, CA, USA

    • R M Hackman
    • , P J Havel
    • , E M Noceti
    • , J S Stern
    •  & C L Keen
  2. Department of Internal Medicine, University of California, Davis, CA, USA

    • H J Schwartz
    • , J C Rutledge
    • , J S Stern
    •  & C L Keen
  3. Department of Statistics, California State University, East Bay, CA, USA

    • M R Watnik
  4. Department of Pharmacy Science, Creighton University, Omaha, USA

    • S J Stohs

Authors

  1. Search for R M Hackman in:

  2. Search for P J Havel in:

  3. Search for H J Schwartz in:

  4. Search for J C Rutledge in:

  5. Search for M R Watnik in:

  6. Search for E M Noceti in:

  7. Search for S J Stohs in:

  8. Search for J S Stern in:

  9. Search for C L Keen in:

Corresponding author

Correspondence to R M Hackman.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/sj.ijo.0803283